Actinic Keratosis

  • Francisco M. Camacho-MartinezEmail author


Solar keratosis. This term is more specific because “actinic” means that the keratosis is produced by rays of any kind, unlike “solar” that indicates specifically rays of the sun. In several countries, it is also known as senile keratosis, senile hyperkeratosis, keratoma senile and keratosis senilis.





Actinic keratoses


5-aminolevulinic acid


Squamous intraepithelial neoplasia


Carbon dioxide


Computer pattern generator


Diclofenac sodium


High-definition optical coherence tomography


Ingenol mebutate gel




Keratinocytic intraepithelial neoplasia


Light-emitting diodes


Methyl ester 5-aminolevulinic acid


Photodynamic therapy


Photosensitiser protoporphyrin IX


Randomised controlled trials


Squamous-cell carcinoma


Ultraviolet radiation


Strength of recommendation taxonomy


Sun protection factor


  1. Ackerman AB. Respect at last for solar keratosis. Dermatopathol. 1997;3:101–3.Google Scholar
  2. Alsner S, González S, Ulrich M. Actinic keratosis. In: González S, editor. Reflectance confocal microscopy in dermatology: fundamentals and clinical applications. Madrid: Aula Médica Ed; 2012. p. 69–71.Google Scholar
  3. Askew DA, Mickan SM, Soyer P, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis – a systematic review of randomized controlled trials. Int J Dermatol. 2009;48:453–63.CrossRefGoogle Scholar
  4. Camacho FM. Remodelamiento cutáneo: perspectiva histórica. Piel. 2005a;20:504–17.CrossRefGoogle Scholar
  5. Camacho FM. Medium-depth and deep chemical peels. J Cosmet Dermatol. 2005b;4:117–28.CrossRefGoogle Scholar
  6. Carlson S, Bordeaux J. Treatment of actinic keratoses. In: Maibach HI, Gorouhi F, editors. Evidence based dermatology. 2nd ed. Shelton: People’s Medical Publishing House; 2011.Google Scholar
  7. Dirschka T, Bierhoff E, Pflugfelder A, Garbe C. Topical 3.0 % diclofenac in 2.5 % hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. J Eur Acad Dermatol Venereol. 2010;24:258–63.CrossRefGoogle Scholar
  8. Gupta AK, Paquet M. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers. J Cutan Med Surg. 2013;17:173–9.CrossRefGoogle Scholar
  9. Hanke CW, Moy RI, Roenigk RK, Roenigk Jr HH, et al. Current status of surgery in dermatology. J Am Acad Dermatol. 2013;69:972–1001.CrossRefGoogle Scholar
  10. Hirokawa D, Lee JB. Dermatoscopy: an overview of subsurface morphology. Clin Dermatol. 2011;29:557–65.CrossRefGoogle Scholar
  11. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157 Suppl 2:34–40.CrossRefGoogle Scholar
  12. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010–9.CrossRefGoogle Scholar
  13. Lecha CM. Photoprotection and sunscreen. Monogr Dermatol. 2014;27(Supl.1):104–10.Google Scholar
  14. Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013;68(Supp l):S39–48.CrossRefGoogle Scholar
  15. Schmitt AR, Bordeaux JS. Solar keratoses: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin Dermatol. 2013;31:712–7.CrossRefGoogle Scholar
  16. Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5 % imiquimod cream treatment: a long-term follow-up study. Arch Dermatol. 2004;140:1542.CrossRefGoogle Scholar
  17. Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;65:1101–8.CrossRefGoogle Scholar
  18. Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol. 2012;22:370–4.PubMedGoogle Scholar
  19. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5 % and 3.75 % for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-weeks cycles. J Am Acad Dermatol. 2010;62:582–90.CrossRefGoogle Scholar
  20. Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159:205–10.CrossRefGoogle Scholar
  21. Weiss ET, Brauer JA, Anolik R, Reddy KK, et al. 1927-nm fractional resurfacing of facial actinic keratoses: a promising new therapeutic option. J Am Acad Dermatol. 2013;68:98–102.CrossRefGoogle Scholar
  22. Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169:502–18.CrossRefGoogle Scholar
  23. Werner RN, Stockfleth E, Connolly SM, Correia O, et al. International League of Dermatological Societies (ILDS) Evidence-based (S3) Guidelines for the reatment of Actinic Keratosis (ICD L57.0:D04). In cooperation with the European Dermatology Forum (EDF), 2015 (in press)Google Scholar
  24. Zalaudek I, Giacomel J, Schmid K, Bondino S, et al. Dermatoscopy of facial actinic keratoses, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J Am Acad Dermatol. 2012;66:589–97.CrossRefGoogle Scholar

Further Reading

  1. Ballester-Sanchez R, Botella-Estrada R. Etiologic and epidemiologic factor of actinic keratoses. Monogr Dermatol. 2013;26 Suppl 1:11–3.Google Scholar
  2. Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis. 2012;89:241–50.PubMedGoogle Scholar
  3. Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol. 1997;36:650–3.CrossRefGoogle Scholar
  4. Camacho FM. Actinic keratosis. Introduction. Concept and classification. Monogr Dermatol. 2014;27 Suppl 1:3–5.Google Scholar
  5. Camacho FM, García-Hernández MJ. Modelado cutáneo (resurfacing). Concepto y fundamentos. In: Cisneros JL, Camacho FM, Trelles MA, editors. Láser en Dermatología y Dermocosmética. 2nd ed. Madrid: Grupo Aula Médica, S.L., Ed; 2008. p. 353–65.Google Scholar
  6. Cassarino DS, Barr RJ. SIN, not KIN. J Cutan Pathol. 2009;36:280.CrossRefGoogle Scholar
  7. de Berker D, McGregor JM, Hughes BR. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222–30.CrossRefGoogle Scholar
  8. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT). Am Fam Physician. 2004;69:548–56.PubMedGoogle Scholar
  9. España A. Actinic keratosis and field cancerization. Monogr Dermatol. 2013;26 Suppl 1:6–10.Google Scholar
  10. Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2006;55:537–8.CrossRefGoogle Scholar
  11. Fitzpatrick TB. The skin cancer cascade: from ozone depletion to melanoma. J Dermatol. 1996;28:816–20.CrossRefGoogle Scholar
  12. Garza Rodríguez V, Malvehy J. New diagnostic methods of the actinic keratoses. Monogr Dermatol. 2013;26 Suppl 1:40–50.Google Scholar
  13. Gilaberte Y, Pérez Lorenz JB, Juarranz A. Photodynamic therapy in the diagnosis and treatment of actinic keratoses. Monogr Dermatol. 2013;26 Suppl 1:51–8.Google Scholar
  14. Gras J. Ingenol mebutate: a new option for actinic keratosis treatment. Drugs Today (Barc). 2013;49:15–22.CrossRefGoogle Scholar
  15. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126:1251–5.CrossRefGoogle Scholar
  16. Hepplewhite A. Management of patients with actinic keratoses. Br J Nurs. 2012;21(Suppl):S27–30.CrossRefGoogle Scholar
  17. Jansen R, Wang SQ, Burnett M, Osterwalder U, Lim HW. Photoprotection. Part I. Photoprotection by naturally occurring, physical, and systemic agents. J Am Acad Dermatol. 2013;69:853–64.CrossRefGoogle Scholar
  18. Jansen R, Wang SQ, Burnett M, Osterwalder U, Lim HW. Photoprotection. Part II. Sunscreen: development, efficacy, and controversial. J Am Acad Dermatol. 2013;69:867–80.CrossRefGoogle Scholar
  19. Jorizzo J, Dinehart S, Matheson R, Moore JK, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57:265–8.CrossRefGoogle Scholar
  20. Maier T, Braun-Falco M, Laubender RP, Ruzicka T, Berking C. Actinic keratosis in the en-face and slice imaging mode of high-definition optical coherence tomography and comparison with histology. Br J Dermatol. 2013;168:120–8.CrossRefGoogle Scholar
  21. Melkonian S, Argos M, Pierce BL, Chen Y, Islam T, Ahmed A, et al. A prospective study of the synergistic effects of arsenic exposure and smoking, sun exposure, fertilizer use, and pesticide use on risk of premalignant skin lesions in Bangladeshi men. Am J Epidemiol. 2011;173:183–91.CrossRefGoogle Scholar
  22. Ondo AL, Padilla S, Miedler JD, Cockerell CJ, et al. Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study. Dermatol Surg. 2012;38:1469–76.CrossRefGoogle Scholar
  23. Poziomcyk CS, Dornelles MA, Köche B, Dornelles SI. Pain evaluation in the cryosurgery of actinic keratoses. An Bras Dermatol. 2011;86:645–50.CrossRefGoogle Scholar
  24. Rios Martín JJ. Histopathology of actinic keratoses. Histopathological forms. Monogr Dermatol. 2013;26 Suppl 1:26–30.Google Scholar
  25. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66:486–93.CrossRefGoogle Scholar
  26. Sander CA, Pfeiffer C, Kligman AM, Plewig G. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol. 1997;36:236–8.CrossRefGoogle Scholar
  27. Slaughter DP, Southwick HW, Smejkal W. Field cancerization on oral stratified squamous epithelium. Cancer (Phila). 1953;6:963–8.CrossRefGoogle Scholar
  28. Xu D, Yuan R, Gu H, et al. The effect of ultraviolet radiation on the transforming growth factor beta 1/Smads pathway and p53 in actinic keratosis and normal skin. Arch Dermatol Res. 2013;305:777–86.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Medical-Surgical Dermatology Department, Hospital Universitario Virgen Macarena, School of MedicineUniversity of SevilleSevilleSpain

Personalised recommendations